Halozyme Therapeutics | HALO - Operating Profit


Halozyme Therapeutics reported $-88.41M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amarin USD -1.7M 8.47M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Baxter International USD -214.2M 415.4M Dec/2025
Cara Therapeutics USD -2.39M 3.49M Mar/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Esperion Therapeutics USD -16.03M 18.6M Sep/2024
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
MannKind USD -69.24M 28.19M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Pfizer USD 4.65B 3.99B Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
United Therapeutics USD -14.6M 403.9M Dec/2025
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024